[go: up one dir, main page]

MX2013012688A - Polipeptido de fusion presentador de una secuencia de aminoacidos y uso del mismo. - Google Patents

Polipeptido de fusion presentador de una secuencia de aminoacidos y uso del mismo.

Info

Publication number
MX2013012688A
MX2013012688A MX2013012688A MX2013012688A MX2013012688A MX 2013012688 A MX2013012688 A MX 2013012688A MX 2013012688 A MX2013012688 A MX 2013012688A MX 2013012688 A MX2013012688 A MX 2013012688A MX 2013012688 A MX2013012688 A MX 2013012688A
Authority
MX
Mexico
Prior art keywords
amino acid
polypeptide
acid sequence
fusion polypeptide
derived
Prior art date
Application number
MX2013012688A
Other languages
English (en)
Other versions
MX340329B (es
Inventor
Christian Scholz
Michael Schraeml
Herbert Andres
David Casagolda Vallribera
Hartmut Duefel
Michael Gerg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013012688A publication Critical patent/MX2013012688A/es
Publication of MX340329B publication Critical patent/MX340329B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)

Abstract

En la presente descripcion se da a conocer un polipéptido de fusión según la fórmula I: NH2-S2-X1-S1-COOH en donde: X1 comprende una secuencia de aminoácidos aleatoria o una secuencia de aminoácidos derivada de un primer polipéptido, S2 y S1 son secuencias de aminoácidos no solapantes derivadas de un segundo polipéptido, y se refiere a un enlace peptídico, en donde el segundo polipéptido es un polipéptido con actividad de peptidil-prolil cis/transisomerasa (actividad de PPIasa) o se deriva de la familia de dominios de pliegue de FKBP, en donde X1 se inserta en lugar del dominio de inserción en solapa del segundo polipéptido.
MX2013012688A 2011-05-05 2012-05-04 Polipeptido de fusion presentador de una secuencia de aminoacidos y uso del mismo. MX340329B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11164957 2011-05-05
EP12155742 2012-02-16
PCT/EP2012/058207 WO2012150320A1 (en) 2011-05-05 2012-05-04 Amino acid sequence presenting fusion polypeptide and its use

Publications (2)

Publication Number Publication Date
MX2013012688A true MX2013012688A (es) 2013-12-02
MX340329B MX340329B (es) 2016-07-06

Family

ID=46022284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012688A MX340329B (es) 2011-05-05 2012-05-04 Polipeptido de fusion presentador de una secuencia de aminoacidos y uso del mismo.

Country Status (17)

Country Link
US (5) US9266962B2 (es)
EP (2) EP2705053B1 (es)
JP (3) JP6165713B2 (es)
KR (1) KR101632479B1 (es)
CN (2) CN103620031B (es)
AR (1) AR086250A1 (es)
AU (1) AU2012251584B2 (es)
BR (1) BR112013028134A2 (es)
CA (2) CA2831162C (es)
ES (1) ES2637667T3 (es)
IL (1) IL228983A0 (es)
MX (1) MX340329B (es)
MY (1) MY166542A (es)
RU (1) RU2630660C2 (es)
SG (1) SG194707A1 (es)
WO (2) WO2012150321A1 (es)
ZA (1) ZA201308251B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
ES2603589T3 (es) * 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
JP6490574B2 (ja) * 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
CA2945066A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Her1 antigen binding proteins binding to the beta-hairpin of her1
JP6695812B2 (ja) * 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
RU2017123283A (ru) 2014-12-01 2019-01-09 Пфенекс Инк. Партнеры по слиянию для получения пептидов
KR20170095364A (ko) * 2014-12-18 2017-08-22 비오메리으 합성 이중-에피토프 화합물
CA2971402C (en) 2014-12-19 2023-08-01 F. Hoffmann-La Roche Ag Microbial transglutaminases, substrates therefor and methods for the use thereof
CA2986388C (en) 2015-06-11 2024-02-27 Genexine, Inc. Modified interleukin-7 protein and uses thereof
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
KR102604595B1 (ko) 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
WO2017095191A1 (ko) 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JPWO2019167874A1 (ja) * 2018-02-27 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット
JP7712917B2 (ja) 2019-09-26 2025-07-24 エフ． ホフマン－ラ ロシュ アーゲー 抗ｃｓｆ－１ｒ抗体
CN117529662A (zh) 2021-06-17 2024-02-06 豪夫迈·罗氏有限公司 热稳定的亲和多肽
EP4380955A1 (en) * 2021-08-06 2024-06-12 Roche Diagnostics GmbH Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
CN116284220B (zh) * 2023-02-24 2024-08-20 浙江兴业集团有限公司 一种胆固醇酯酶抑制多肽组合及其制备方法、应用
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling
CN120965876A (zh) * 2024-08-16 2025-11-18 上海津伦克咨询管理有限公司 一种对igf-1具有高亲和力的抗体
CN118791609B (zh) * 2024-09-13 2024-11-26 江苏凯基生物技术股份有限公司 一种抗igf-1的单克隆抗体及制备方法及试剂盒及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1232188A (en) * 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
CA2432716A1 (en) 2000-12-26 2002-07-04 Sekisui Chemical Co., Ltd. Process for producing recombinant protein and fused protein
BRPI0210598B8 (pt) * 2001-06-22 2021-05-25 Hoffmann La Roche processos para a produção de um complexo solúvel que compreende uma proteína amiloidogênica alvo e uma chaperona peptidil-prolil-isomerase, para a produção de um complexo de glicoproteína retroviral de superfície-chaperona solúvel, e para detectar pelo menos um anticorpo para uma glicoproteína retroviral de superfície em uma amostra, bem como complexo solúvel, e composição
AU2003243969B2 (en) 2002-06-25 2008-03-13 Sekisui Chemical Co., Ltd. Expression vector, host, fused protein, process for producing fused protein and process for producing protein
ATE374784T1 (de) * 2002-12-20 2007-10-15 Hoffmann La Roche Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
US20070026501A1 (en) 2003-04-18 2007-02-01 Joe Chiba Immunogen, composition for immulogical use and process for producing antibody using the same
US7732564B2 (en) * 2005-04-28 2010-06-08 London Health Sciences Centre Research Inc. Serum tumor marker in rodent prostate cancer models
EP2279726A3 (en) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP1780282B1 (en) 2005-10-26 2010-12-08 Roche Diagnostics GmbH Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
CA2562738C (en) * 2005-10-26 2011-07-12 F. Hoffmann-La Roche Ag Soluble rubella e1 envelope antigens
EP1971684B1 (en) * 2006-01-03 2011-10-05 Roche Diagnostics GmbH Chimaeric fusion protein with superior chaperone and folding activities
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
EA201100741A1 (ru) * 2008-11-10 2012-01-30 Новартис Аг Антитела к модифицированным пептидам ифр-1/е человека
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
JP6488854B2 (ja) * 2015-04-22 2019-03-27 住友電気工業株式会社 半導体積層体および受光素子

Also Published As

Publication number Publication date
KR20140004802A (ko) 2014-01-13
BR112013028134A2 (pt) 2016-11-29
AU2012251584A1 (en) 2013-11-07
US20160137728A1 (en) 2016-05-19
CN103620031B (zh) 2016-11-23
US20140178393A1 (en) 2014-06-26
NZ616871A (en) 2015-12-24
US20140120561A1 (en) 2014-05-01
US10301383B2 (en) 2019-05-28
EP2705147A1 (en) 2014-03-12
US10647765B2 (en) 2020-05-12
US20190367601A1 (en) 2019-12-05
CN103620031A (zh) 2014-03-05
JP2017048209A (ja) 2017-03-09
IL228983A0 (en) 2013-12-31
CN103649119B (zh) 2016-06-08
US9938340B2 (en) 2018-04-10
EP2705147B1 (en) 2019-08-07
CA2831162A1 (en) 2012-11-08
WO2012150320A1 (en) 2012-11-08
JP6165713B2 (ja) 2017-07-19
AU2012251584B2 (en) 2016-07-28
EP2705053B1 (en) 2017-06-14
MX340329B (es) 2016-07-06
RU2013152691A (ru) 2015-06-10
ZA201308251B (en) 2014-08-27
SG194707A1 (en) 2013-12-30
CA2831162C (en) 2019-05-28
ES2637667T3 (es) 2017-10-16
MY166542A (en) 2018-07-16
CN103649119A (zh) 2014-03-19
WO2012150321A1 (en) 2012-11-08
JP5877893B2 (ja) 2016-03-08
EP2705053A1 (en) 2014-03-12
AR086250A1 (es) 2013-11-27
JP2014515761A (ja) 2014-07-03
JP2014520073A (ja) 2014-08-21
US20160138004A1 (en) 2016-05-19
KR101632479B1 (ko) 2016-06-21
RU2630660C2 (ru) 2017-09-11
US9266962B2 (en) 2016-02-23
CA2834456A1 (en) 2012-11-08
US9273144B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
MX2013012688A (es) Polipeptido de fusion presentador de una secuencia de aminoacidos y uso del mismo.
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
MY160552A (en) Low protein infant formula with increased essential amino acids
NZ702053A (en) Anti-human trop-2 antibody having antitumor activity in vivo
NZ598356A (en) Antigenic tau peptides and uses thereof
GB2492267B (en) Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals and amino acids
CA2811364C (en) Methods and compositions for inhibiting viral entry into cells
MY170094A (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
IN2014DN09922A (es)
MX2013011859A (es) Adhesivo de cianocrilato con resistencia mejorada a agua.
MX2014013329A (es) Variantes de enzimas mejoradas.
MY188723A (en) Oleanoyl peptide composition and collagen enhancement
MX354156B (es) Dipeptido que comprende un aminoacido no proteogenico.
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
WO2013021212A3 (en) Modified osteopontin peptides having an inactivated rgd domain and uses thereof
WO2014004540A8 (en) Method for engineering proteases and protein kinases
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
NZ724133A (en) Tfpi inhibitors and methods of use
SG10201909517WA (en) Learning and memory improver
WO2011107948A3 (en) Ligands of insulin degrading enzyme and their uses
NZ600818A (en) Cyclic peptides for the regulation of vectorial ion channels
EP3536190A3 (en) Brush with alternate rows of angled tufts
NZ738982A (en) Composition comprising amino acid and cyclic dipeptide
RU2012110908A (ru) Синтетические пептиды с ненаркотическим типом анальгетического действия
RU2013119051A (ru) Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями

Legal Events

Date Code Title Description
FG Grant or registration